🇺🇸 Femoston Conti in United States

108 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fatigue — 17 reports (15.74%)
  2. Headache — 17 reports (15.74%)
  3. Myalgia — 12 reports (11.11%)
  4. Diarrhoea — 11 reports (10.19%)
  5. Vision Blurred — 11 reports (10.19%)
  6. Arthralgia — 10 reports (9.26%)
  7. Cough — 8 reports (7.41%)
  8. Nausea — 8 reports (7.41%)
  9. Disturbance In Attention — 7 reports (6.48%)
  10. Muscle Spasms — 7 reports (6.48%)

Source database →

Femoston Conti in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Femoston Conti approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Femoston Conti in United States?

Royal Brompton & Harefield NHS Foundation Trust is the originator. The local marketing authorisation holder may differ — check the official source linked above.